Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefuroxime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 0.86 |
| ▸ | POLB | P06746 | 2/20 | 0.86 |
| ▸ | PKM | P14618 | 2/20 | 0.86 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.86 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.78 |
| ▸ | PDE4A | P27815 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.59 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.59 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.59 |
| ▸ | ALB | P02768 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefuroxime SCHEMBL31472986 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL10907122 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL40413 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL40415 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL11243712 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL2221559 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL11549178 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL3861498 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL20535121 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL40414 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| CN-117320735-A | Engineered probiotic compositions and uses thereof | 哈佛大学校长及研究员协会 | 2023-12-29 | — | — | CN | claimed |
| CN-116203152-A | Method for determining beta-lactam content in veterinary drug preparation by PRiME HLB-high performance liquid chromatography-tandem mass spectrometry | 石家庄海关技术中心 | 2023-06-02 | — | — | CN | claimed |
| US-11583544-B2 | Remote loading of sparingly water-soluble drugs into lipid vesicles | CELATOR PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | claimed |
| WO-2022089417-A1 | DRUG FOR TREATING SPONDYLOPATHIES AND OSTEOARTHROPATHY AND RELIEVING PAIN CAUSED THEREBY, AND APPLICATION THEREOF | 陕西秦岭七药协同创新中心有限公司 | 2022-05-05 | — | — | WO | claimed |
| CN-112321610-B | Ceclozapine sulfate and preparation method and application thereof | 湖南润星制药有限公司 | 2022-04-19 | — | — | CN | claimed |
| CN-114015717-A | Rapid genetic transformation method for grape callus | 南京农业大学 | 2022-02-08 | — | — | CN | claimed |
| US-4602012-A | Cephalosporin antibiotics | GLAXO GROUP LIMITED (GB) | 1986-07-22 | — | — | US | claimed |
| US-4446317-A | CEFUROXIME ESTERS | GLAXO OPERATIONS U.K. LIMITED (GB) | 1984-05-01 | — | — | US | claimed |
| US-4287181-A | TO ENHANCE THE EFFECTIVENESS OF B-LACTAM ANTIBIOTICS | PFIZER INC. (US) | 1981-09-01 | — | — | US | claimed |
| US-4284767-A | Process for preparing 3-carbamoyloxymethyl cephalosporins | GLAXO GROUP LIMITED (GB) | 1981-08-18 | — | — | US | claimed |
| US-4267320-A | ESTERS OF A 7-/2-/FUR-2-YL/-2-METHOXYIMINOACETAMIDO DERIVATIVES; ORAL | GLAXO LABORATORIES LIMITED (GB) | 1981-05-12 | — | — | US | claimed |
| US-4258183-A | Process for the preparation of cephalosporin compounds | GLAXO GROUP LIMITED (GB) | 1981-03-24 | — | — | US | claimed |
| CN-122036818-A | Synthesis of 3-fucosyllactose | 天津科技大学 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026102307-A1 | ACELLULAR BLOOD ALTERNATIVE FOR TRANSFUSION AND ORGAN PERFUSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260112038-A1 | METHODS AND RELATED ASPECTS FOR ANTIBIOTIC SUSCEPTIBILITY TESTING | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2026-04-23 | — | — | US | disclosed |
| US-4267320-A | ESTERS OF A 7-/2-/FUR-2-YL/-2-METHOXYIMINOACETAMIDO DERIVATIVES; ORAL | GLAXO LABORATORIES LIMITED (GB) | 1981-05-12 | — | — | US | disclosed |
| US-4258183-A | Process for the preparation of cephalosporin compounds | GLAXO GROUP LIMITED (GB) | 1981-03-24 | — | — | US | disclosed |
| US-4128715-A | LYSINE SALT OF CERFUROXIME | GLAXO LABORATORIES LIMITED (GB) | 1978-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260112038-A1 | METHODS AND RELATED ASPECTS FOR ANTIBIOTIC SUSCEPTIBILITY TESTING | LAS1L, LSS, SET | TDP1 3124/4885HSD17B10 4448/4885NR1I2 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.